Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
People with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, active pancreatitis, or severe gastroparesis should not take GLP-1 agonists at all
The peptide sits on the skins surface
Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available
| Certificate archived via blockchain legally binding Conclusion Q/SH-VL-2026ChP 2020USP-NFEP 11.0 All test items of this batch meet the in-house quality specification and comply with ChP 2020, USP-NF, and EP 11.0 pharmacopoeial requirements
MEDICAL & LEGAL DISCLAIMER The information contained in this article is intended for licensed healthcare providers and qualified medical professionals only
